{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:41:08Z","timestamp":1764700868796,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clml.2021.04.006","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:39:28Z","timestamp":1621946368000},"page":"e680-e685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review"],"prefix":"10.1016","volume":"21","author":[{"given":"Oleksandra","family":"Lupak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xiaoxia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannan","family":"Thanikachalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"Jabbour-Aida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shatha","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Emole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.04.006_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.04.006_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.04.006_bib0003","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.006_bib0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12562","article-title":"Incidence of haematological malignancies by ethnic group in England, 2001-7","volume":"163","author":"Shirley","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.04.006_bib0005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.006_bib0006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.04.006_bib0007","first-page":"328","article-title":"Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital","volume":"6","author":"Yun","year":"2016","journal-title":"J Stem Cell Res Ther"},{"key":"10.1016\/j.clml.2021.04.006_bib0008","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.04.006_bib0009","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","article-title":"Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95\u00a0MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.04.006_bib0010","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.clml.2017.10.008","article-title":"Modified HyperCVAD versus bortezomib-HyperCAD in patients with relapsed\/refractory multiple myeloma","volume":"18","author":"Saraceni","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.04.006_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2","article-title":"HyperCVAD for VAD-resistant multiple myeloma","volume":"52","author":"Dimopoulos","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.04.006_bib0012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0609.2008.01131.x","article-title":"Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE","volume":"81","author":"Srikanth","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.04.006_bib0013","doi-asserted-by":"crossref","unstructured":"Joshua T.V., Rizzo J.D., Zhang M.J., et\u00a0al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer 2010;116:3469\u201376. https:\/\/doi.org\/10.1002\/cncr.25297. PMID: 20564154; PMCID: PMC3153958.","DOI":"10.1002\/cncr.25297"},{"key":"10.1016\/j.clml.2021.04.006_bib0014","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Sikander","year":"2019","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:22Z","timestamp":1761870922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502100149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S215226502100149X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}